Since its creation, SeaBeLife has raised €8 million in capital and financing. In October 2020, we closed a €2 million pre-Series A round to accelerate the entry of SBL03 into the clinical phase, ahead of an €8 million Series A round to achieve clinical proof of concept for our two programs and initiate industrial partnerships..
Each program targets a potential market estimated at over €5 billion, with patents already granted in Europe and the United States.
SeaBeLife has won several competitions, including the i-Nov competition (France 2030) in 2024.
Any question?
Contact-us : contact@seabelife.com
